Cyclin‐dependent kinases as therapeutic targets in cancer: Recent advances, challenges, and opportunities
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70442 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Ning Ju und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cell Structure and Function, College of Life Sciences, Shandong Provincial Key Laboratory of Animal Resistance Biology, Collaborative Inno…. Hauptthemen laut MEDLINE: Neoplasms, Cyclin-Dependent Kinases, Molecular Targeted Therapy, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 114 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Dysregulated cell cycle progression drives uncontrolled proliferation and is a fundamental hallmark of cancer, making cyclin‐dependent kinases (CDKs), which largely govern cell‐cycle progression and cell division, attractive therapeutic targets. Currently, CDK inhibitors (CDKIs), particularly agents targeting CDK4/6, have shown clinical activity in HR + /HER 2− metastatic breast cancer. Recent structural elucidation of the CDK2 catalytic domain and its allosteric sites has enabled the development of several selective CDK2 inhibitors, many of which have exhibited encouraging antitumor activity. Moreover, emerging evidence further indicates that dual inhibition of CDK4/6 and CDK2 can synergistically overcome resistance to CDK4/6 blockade. Notably, recent studies have revealed that CDKIs can induce cellular senescence and enhance the efficacy of cancer immunotherapy. In this review, we outline the CDK family and their key functions in cell cycle control, summarize recent clinical advances in CDKI‐based therapies, with emphasis on CDK4/6 and CDK2 inhibition, and discuss opportunities to integrate CDK‐targeted therapy with immunotherapy and other therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cell Structure and Function, College of Life Sciences, Shandong Provincial Key Laboratory of Animal Resistance Biology, Collaborative Innovation Center of Cell Biology in Universities of Shandong, Shandong No…
- State Key Laboratory of Medicinal Chemical Biology, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Protein Science, College of Life Sciences, Nankai University, Tianjin, China.
ORCID-Profile: Feifei Qi
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- China Postdoctoral Science Foundation
Zitieren
APA
Ju, N., Zhao, L., Yin, S., Yang, X., Zhou, J., Gao, J., & Qi, F. (2026). Cyclin‐dependent kinases as therapeutic targets in cancer: Recent advances, challenges, and opportunities. International Journal of Cancer. https://doi.org/10.1002/ijc.70442
Vancouver
Ju N, Zhao L, Yin S, Yang X, Zhou J, Gao J, et al. Cyclin‐dependent kinases as therapeutic targets in cancer: Recent advances, challenges, and opportunities. International Journal of Cancer. 2026. doi:10.1002/ijc.70442
BibTeX
@article{Ju2026,
author = {Ju, Ning and Zhao, Li and Yin, Shanshan and Yang, Xiangrui and Zhou, Jun and Gao, Jinmin and Qi, Feifei},
title = {Cyclin‐dependent kinases as therapeutic targets in cancer: Recent advances, challenges, and opportunities},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70442}
}
EUVIMED